By Robert Michel, from the Volume XXVI No. 8 – June 10, 2019 issue
Digital pathology is coming in a big way to two regions in two different nations. In the United Kingdom, it was announced on May 30 that the North Tees and Hartlepool NHS Foundation in the north of England signed a five-year contract with Sectra of Linköping, Sweden. Sectra is to deliver a “regional digital pathology solution” in
By R. Lewis Dark, from the Volume XXVI No. 7 – May 20, 2019 issue
INTERESTING THINGS ARE UNFOLDING within the profession of anatomic pathology. If the adage of “follow the money” applies to understanding why things happen, then recent events support some surprising conclusions.
Take the news reported in this issue of The Dark Report that PathGroup of Nashville is acquiring Pathologists Bio-Medical Laboratories (PBML) of Dallas. That brings together two regional
By Robert Michel, from the Volume XXVI No. 6 – April 29, 2019 issue
Investor interest in digital pathology (DP) and the use of artificial intelligence (AI) to analyze digital pathology images seems to be at a fever pitch recently. In the last three weeks, investors poured almost $85 million of capital into just three digital pathology companies, as noted below. This activity may be a sign that certain DP
By Mary Van Doren, from the Volume XXV No. 18 – December 24, 2018 issue
CEO SUMMARY: This year’s list of the Top 10 Lab Industry Stories for 2018 is dominated by new directives from Medicare and private health insurers, as well as significant decisions by federal courts. Collectively, these developments create new compliance risks for all clinical laboratories and anatomic pathology groups. What is more notable about these top
By Joseph Burns, from the Volume XXV No. 18 – December 24, 2018 issue
TO SHORTEN THE TIME FOR CANCER DIAGNOSES, the United Kingdom’s National Health Service (NHS) will open five new digital pathology and imaging centers that will use artificial intelligence. The digital pathology and imaging centers will open in Coventry, Glasgow, Leeds, London, and Oxford.
Last month, the UK government announced that it will invest £50 million ($68.9
By Robert Michel, from the Volume XXV No. 18 – December 24, 2018 issue
CEO SUMMARY: This year’s list of the Top 10 Lab Industry Stories for 2018 is dominated by new directives from Medicare and private health insurers, as well as significant decisions by federal courts. Collectively, these developments create new compliance risks for all clinical laboratories and anatomic pathology groups. What is more notable about these top
By Joseph Burns, from the Volume XXV No. 3 – February 12, 2018 issue
CEO SUMMARY: Now that the FDA has cleared a digital pathology for use in primary diagnosis, interest in DP is building. Inspirata purchased Omnyx and its assets because the Omnyx Dynamyx digital pathology software has strong features that could be integrated into Inspirata’s digital pathology solution. In this interview with THE DARK REPORT, Inspirata CEO
By Robert Michel, from the Volume XXIV, No. 17 – December 11, 2017 issue
To deal with a shortage of surgical pathologists in the United Kingdom, the British National Health Service (NHS) is looking at solutions, such as deployment of digital pathology systems. According to a story in Pharma Times, the NHS is negotiating with Roche Diagnostics and partners to develop a program to implement digital pathology systems across the
By Robert Michel, from the Volume XXIV, No. 17 – December 11, 2017 issue
1. CMS Sticks by Decision to Deeply Cut Medicare Part B Lab Test Fees
SHORT OF A MIRACLE, the clinical laboratory industry is less than three weeks from the single most financially-disruptive event of the past 30 years. On Jan. 1, the federal Centers for Medicare and Medicaid Services will impose deep cuts to Part B
By Robert Michel, from the Volume XXIV, No. 17 – December 11, 2017 issue
CEO SUMMARY: In hindsight, 2017 is likely to be remembered as a milestone year that launched several disruptive developments that will reshape the lab industry moving forward. For the clinical laboratory sector this year, CMS confirmed its intent to slash Part B clinical laboratory test prices aggressively, effective Jan. 1. For the anatomic pathology sector
